Remus Pharmaceuticals Limited — Others, 16-04-2025: Certificate under SEBI (Depositories and Participants) Regulations, 2018

Remus Pharmaceuticals has announced a board meeting on the Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2025. The report indicates the company's equity share capital stands at 58,92,000 shares, with 84.28% held in dematerialized form through CDSL and 15.72% through NSDL. The company’s capital structure is updated, and there are no pending demat requests or significant discrepancies noted.

This transparency in capital structure could foster positive sentiment among investors, indicating good governance practices. Investors might see this as a sign of operational stability and efficient share management, minimizing risks associated with share discrepancies.